Improving cardiac Ca2+ transport into the sarcoplasmic reticulum in heart failure: Lessons from the ubiquitous SERCA2b Ca2+ pump

Biochemical Society Transactions

Volumn 39, Issue 3, 2011, Pages 781-787

  Vangheluwe, Peter ^a   Wuytack, Frank ^a  

^a LABORATORY OF MOLECULAR AND CELLULAR SIGNALING   (Belgium)

Author keywords

Calcium transport ATPase; Cardiac contractility; Heart failure; Phospholamban; Sarcoplasmic endoplasmic reticulum Ca2+ ATPase (SERCA); Transmembrane regulator

Indexed keywords

ADENOSINE TRIPHOSPHATASE (CALCIUM); ADENOSINE TRIPHOSPHATASE (POTASSIUM SODIUM); ADENOSINE TRIPHOSPHATASE (POTASSIUM SODIUM) ALPHA; ADENOSINE TRIPHOSPHATASE (POTASSIUM); CALCIUM ION; MEMBRANE PROTEIN; PHOSPHOLAMBAN; SARCOPLASMIC RETICULUM CALCIUM TRANSPORTING ADENOSINE TRIPHOSPHATASE; SARCOPLASMIC RETICULUM CALCIUM TRANSPORTING ADENOSINE TRIPHOSPHATASE 1A; SARCOPLASMIC RETICULUM CALCIUM TRANSPORTING ADENOSINE TRIPHOSPHATASE 2; SARCOPLASMIC RETICULUM CALCIUM TRANSPORTING ADENOSINE TRIPHOSPHATASE 2B; THAPSIGARGIN; TRANSMEMBRANE PROTEIN 11; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; BETA CHAIN; BINDING AFFINITY; BINDING SITE; CALCIUM TRANSPORT; CARBOXY TERMINAL SEQUENCE; CONFERENCE PAPER; CRYSTALLIZATION; DRUG BINDING; ENDOPLASMIC RETICULUM; GENE EXPRESSION; HEART FAILURE; HEART FUNCTION; HEART MUSCLE CELL; HEART MUSCLE CONTRACTILITY; HOSPITALIZATION; HUMAN; MORTALITY; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; PROTEIN PURIFICATION; PROTEIN STRUCTURE; REGULATORY MECHANISM; SARCOPLASMIC RETICULUM; STRUCTURAL HOMOLOGY; UBIQUITINATION;

CALCIUM; HEART FAILURE; ISOENZYMES; MODELS, MOLECULAR; MYOCARDIAL CONTRACTION; MYOCARDIUM; PROTEIN CONFORMATION; SARCOPLASMIC RETICULUM; SARCOPLASMIC RETICULUM CALCIUM-TRANSPORTING ATPASES; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 79957499315     PISSN: 03005127     EISSN: 14708752     Source Type: Journal    
DOI: 10.1042/BST0390781     Document Type: Conference Paper

References (48)

1. Bers, D.M. (2002) Cardiac excitation-contraction coupling. Nature 415, 198-205
2. 2+ homeostasis and cardiac contractility. J. Mol. Cell. Cardiol. 33, 1053-1063
3. 2+ ATPase 2 (SERCA2) activity: cell biological implications. Cell Calcium 38, 291-302
4. Vandecaetsbeek, I., Raeymaekers, L., Wuytack, F. and Vangheluwe, P. (2009) Factors controlling the activity of the SERCA2a pump in the normal and failing heart. Biofactors 35, 484-499
5. 2+-ATPase expression in the hypertrophic and failing heart. Can. J. Physiol. Pharmacol. 84, 509-521
6. Misquitta, C.M., Chen, T. and Grover, A.K. (2006) Control of protein expression through mRNA stability in calcium signalling. Cell Calcium 40, 329-346 (Pubitemid 44307907)
7. Andersson, K.B., Birkeland, J.A., Finsen, A.V., Louch, W.E., Sjaastad, I., Wang, Y., Chen, J., Molkentin, J.D., Chien, K.R., Sejersted, O.M. and Christensen, G. (2009) Moderate heart dysfunction in mice with inducible cardiomyocyte-specific excision of the Serca2 gene. J. Mol. Cell. Cardiol. 47, 180-187
8. 2+-ATPase 2 gene transcript. Biochem. J. 322, 885-891
9. Lytton, J., Westlin, M., Burk, S.E., Shull, G.E. and MacLennan, D.H. (1992) Functional comparisons between isoforms of the sarcoplasmic or endoplasmic reticulum family of calcium pumps. J. Biol. Chem. 267, 14483-14489
10. 2+-ATPase isoform SERCA2a by the nonmuscle SERCA2b homologue causes mild concentric hypertrophy and impairs contraction-relaxation of the heart. Circ. Res. 89, 838-846
11. 2+ loads only. Circ. Res. 92, 881-887
12. 2+ affinity can lead to severe cardiac hypertrophy, stress intolerance and reduced life span. J. Mol. Cell. Cardiol. 41, 308-317
13. 2+. Biophys. J. 100, 1216-1225
14. 2+ pump and the SERCA2 expression level. Cell Calcium 42, 281-289
15. MacLennan, D.H. and Kranias, E.G. (2003) Phospholamban: a crucial regulator of cardiac contractility. Nat. Rev. Mol. Cell Biol. 4, 566-577
16. MacLennan, D.H., Asahi, M. and Tupling, A.R. (2003) The regulation of SERCA-type pumps by phospholamban and sarcolipin. Ann. N.Y. Acad. Sci. 986, 472-480
17. Bhupathy, P., Babu, G.J., Ito, M. and Periasamy, M. (2009) Threonine-5 at the N-terminus can modulate sarcolipin function in cardiac myocytes. J. Mol. Cell. Cardiol. 47, 723-729
18. 2+ ATPase. Proc. Natl. Acad. Sci. U.S.A. 100, 467-472
19. 2+-ATPase (SERCA) by binding to transmembrane helices alone or in association with phospholamban. Proc. Natl. Acad. Sci. U.S.A. 100, 5040-5045
20. Kawase, Y. and Hajjar, R.J. (2008) The cardiac sarcoplasmic/endoplasmic reticulum calcium ATPase: a potent target for cardiovascular diseases. Nat. Clin. Pract. Cardiovasc. Med. 5, 554-565
21. 2+ affinity in cardiac function. Biochim. Biophys. Acta 1763, 1216-1228
22. Haghighi, K., Schmidt, A.G., Hoit, B.D., Brittsan, A.G., Yatani, A., Lester, J.W., Zhai, J., Kimura, Y., Dorn, 2nd, G.W., MacLennan, D.H. and Kranias, E.G. (2001) Superinhibition of sarcoplasmic reticulum function by phospholamban induces cardiac contractile failure. J. Biol. Chem. 276, 24145-24152
23. Schmitt, J.P., Kamisago, M., Asahi, M., Li, G.H., Ahmad, F., Mende, U., Kranias, E.G., MacLennan, D.H., Seidman, J.G. and Seidman, C.E. (2003) Dilated cardiomyopathy and heart failure caused by a mutation in phospholamban. Science 299, 1410-1413 (Pubitemid 36254657)
24. Haghighi, K., Kolokathis, F., Gramolini, A.O., Waggoner, J.R., Pater, L., Lynch, R.A., Fan, G.C., Tsiapras, D., Parekh, R.R., Dorn, 2nd, G.W. et al. (2006) A mutation in the human phospholamban gene, deleting arginine 14, results in lethal, hereditary cardiomyopathy. Proc. Natl. Acad. Sci. U.S.A. 103, 1388-1393
25. Haghighi, K., Kolokathis, F., Pater, L., Lynch, R.A., Asahi, M., Gramolini, A.O., Fan, G.C., Tsiapras, D., Hahn, H.S., Adamopoulos, S. et al. (2003) Human phospholamban null results in lethal dilated cardiomyopathy revealing a critical difference between mouse and human. J. Clin. Invest. 111, 869-876
26. Luo, W., Grupp, I.L., Harrer, J., Ponniah, S., Grupp, G., Duffy, J.J., Doetschman, T. and Kranias, E.G. (1994) Targeted ablation of the phospholamban gene is associated with markedly enhanced myocardial contractility and loss of β-agonist stimulation. Circ. Res. 75, 401-409
27. Shanmugam, M., Gao, S., Hong, C., Fefelova, N., Nowycky, M.C., Xie, L.H., Periasamy, M. and Babu, G.J. (2011) Ablation of phospholamban and sarcolipin results in cardiac hypertrophy and decreased cardiac contractility. Cardiovasc. Res. 89, 353-361
28. Jaski, B.E., Jessup, M.L., Mancini, D.M., Cappola, T.P., Pauly, D.F., Greenberg, B., Borow, K., Dittrich, H., Zsebo, K.M. and Hajjar, R.J. (2009) Calcium upregulation by percutaneous administration of gene therapy in cardiac disease (CUPID Trial), a first-in-human phase 1/2 clinical trial. J. Card. Fail. 15, 171-181
29. Gwathmey, J.K., Yerevanian, A.I. and Hajjar, R.J. (2011) Cardiac gene therapy with SERCA2a: from bench to bedside. J. Mol. Cell. Cardiol., doi:10.1016/j.yjmcc.2010.11.011
30. Suckau, L., Fechner, H., Chemaly, E., Krohn, S., Hadri, L., Kockskamper, J., Westermann, D., Bisping, E., Ly, H., Wang, X. et al. (2009) Long-term cardiac-targeted RNA interference for the treatment of heart failure restores cardiac function and reduces pathological hypertrophy. Circulation 119, 1241-1252
31. Hoshijima, M., Ikeda, Y., Iwanaga, Y., Minamisawa, S., Date, M.O., Gu, Y., Iwatate, M., Li, M., Wang, L., Wilson, J.M. et al. (2002) Chronic suppression of heart-failure progression by a pseudophosphorylated mutant of phospholamban via in vivo cardiac rAAV gene delivery. Nat. Med. 8, 864-871
32. Toyoshima, C., Nakasako, M., Nomura, H. and Ogawa, H. (2000) Crystal structure of the calcium pump of sarcoplasmic reticulum at 2.6 Å resolution. Nature 405, 647-655 (Pubitemid 30428644)
33. Morth, J.P., Pedersen, B.P., Toustrup-Jensen, M.S., Sorensen, T.L., Petersen, J., Andersen, J.P., Vilsen, B. and Nissen, P. (2007) Crystal structure of the sodium-potassium pump. Nature 450, 1043-1049 (Pubitemid 350273618)
34. Shinoda, T., Ogawa, H., Cornelius, F. and Toyoshima, C. (2009) Crystal structure of the sodium-potassium pump at 2.4 Å resolution. Nature 459, 446-450
35. Pedersen, B.P., Buch-Pedersen, M.J., Morth, J.P., Palmgren, M.G. and Nissen, P. (2007) Crystal structure of the plasma membrane proton pump. Nature 450, 1111-1114 (Pubitemid 350273616)
36. 2+-ATPase pumps ions across the sarcoplasmic reticulum membrane. Biochim. Biophys. Acta 1793, 941-946
37. 2+-ATPase: design of a perfect chemi-osmotic pump. Q. Rev. Biophys. 43, 501-566
38. 2+-transport ATPases. Chem. Rev. 109, 4733-4759
39. 2+ pump. Proc. Natl. Acad. Sci. U.S.A. 106, 18533-18538
40. 2+-transport ATPase (SERCA2a/b). Biochem. J. 303, 979-984
41. 2+-ATPase (SERCA) 1 and 2 isoforms and characterization of Darier disease (SERCA2) mutants by steady-state and transient kinetic analyses. J. Biol. Chem. 278, 47877-47889
42. John, L.M., Lechleiter, J.D. and Camacho, P. (1998) Differential modulation of SERCA2 isoforms by calreticulin. J. Cell Biol. 142, 963-973 (Pubitemid 28402052)
43. Roderick, H.L., Lechleiter, J.D. and Camacho, P. (2000) Cytosolic phosphorylation of calnexin controls intracellular Ca2+ oscillations via an interaction with SERCA2b. J. Cell Biol. 149, 1235-1248
44. Hasler, U., Crambert, G., Horisberger, J.D. and Geering, K. (2001) Structural and functional features of the transmembrane domain of the Na,K-ATPase β subunit revealed by tryptophan scanning. J. Biol. Chem. 276, 16356-16364
45. 2+-ATPases. Biochim. Biophys. Acta, doi:10.1016/j.bbamcr.2010.12.020
46. 2+ transport ATPase by thapsigargin at subnanomolar concentrations. J. Biol. Chem. 266, 13503-13506
47. 2+-ATPase with thapsigargin and thapsigargin analogs. J. Biol. Chem. 285, 28883-28892
48. Takahashi, M., Kondou, Y. and Toyoshima, C. (2007) Interdomain communication in calcium pump as revealed in the crystal structures with transmembrane inhibitors. Proc. Natl. Acad. Sci. U.S.A. 104, 5800-5805